ATE181829T1 - Gaba-erge modulation des augenwachstums - Google Patents

Gaba-erge modulation des augenwachstums

Info

Publication number
ATE181829T1
ATE181829T1 AT94914915T AT94914915T ATE181829T1 AT E181829 T1 ATE181829 T1 AT E181829T1 AT 94914915 T AT94914915 T AT 94914915T AT 94914915 T AT94914915 T AT 94914915T AT E181829 T1 ATE181829 T1 AT E181829T1
Authority
AT
Austria
Prior art keywords
gaba
eye
antagonist
eye growth
ergic
Prior art date
Application number
AT94914915T
Other languages
English (en)
Inventor
Richard A Stone
Alan M Laties
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE181829T1 publication Critical patent/ATE181829T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Cosmetics (AREA)
AT94914915T 1993-04-30 1994-04-26 Gaba-erge modulation des augenwachstums ATE181829T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/056,056 US5385939A (en) 1993-04-30 1993-04-30 GABA-ergic modulation of eye growth

Publications (1)

Publication Number Publication Date
ATE181829T1 true ATE181829T1 (de) 1999-07-15

Family

ID=22001878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914915T ATE181829T1 (de) 1993-04-30 1994-04-26 Gaba-erge modulation des augenwachstums

Country Status (12)

Country Link
US (2) US5385939A (de)
EP (1) EP0701438B1 (de)
JP (1) JP3720047B2 (de)
CN (1) CN1096854C (de)
AT (1) ATE181829T1 (de)
AU (1) AU6713694A (de)
CA (1) CA2160798C (de)
DE (1) DE69419416T2 (de)
DK (1) DK0701438T3 (de)
ES (1) ES2136195T3 (de)
GR (1) GR3031352T3 (de)
WO (1) WO1994025018A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
DE69033775T2 (de) * 1989-06-21 2001-11-15 Trustees Of The University Of Pennsylvania, Philadelphia Verwendung eines Muskarinantagonists zur Herstellung eines Medikaments für die Behandlung und Regulierung der Augenentwicklung
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
KR20040018380A (ko) * 2001-05-25 2004-03-03 밸리 포지 파마슈티컬즈, 인크. 피렌제핀 안약 겔제
US20040023952A1 (en) * 2001-06-20 2004-02-05 Leventhal Audie G. Enhanced brain function by gaba-ergic stimulation
US20060264508A1 (en) * 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
AU2003245995A1 (en) * 2002-06-28 2004-01-19 Novartis Ag Use of gaba-c receptor antagonists for the treatment of myopia
US6713497B1 (en) 2003-03-17 2004-03-30 Brookhaven Science Associates, Llc Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
FI20075498A7 (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
KR102434254B1 (ko) 2016-04-11 2022-08-18 유니버시티 오브 캔버라 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
GB8728483D0 (en) * 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
DE69033775T2 (de) * 1989-06-21 2001-11-15 Trustees Of The University Of Pennsylvania, Philadelphia Verwendung eines Muskarinantagonists zur Herstellung eines Medikaments für die Behandlung und Regulierung der Augenentwicklung
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
DK0701438T3 (da) 1999-11-22
JPH08509739A (ja) 1996-10-15
ES2136195T3 (es) 1999-11-16
EP0701438B1 (de) 1999-07-07
US5385939A (en) 1995-01-31
US5567731A (en) 1996-10-22
AU6713694A (en) 1994-11-21
GR3031352T3 (en) 2000-01-31
DE69419416D1 (de) 1999-08-12
CN1122104A (zh) 1996-05-08
CN1096854C (zh) 2002-12-25
CA2160798A1 (en) 1994-11-10
EP0701438A4 (de) 1997-11-19
WO1994025018A1 (en) 1994-11-10
JP3720047B2 (ja) 2005-11-24
CA2160798C (en) 2005-07-12
DE69419416T2 (de) 1999-10-28
EP0701438A1 (de) 1996-03-20

Similar Documents

Publication Publication Date Title
DK0570594T3 (de)
IE832713L (en) Indole derivatives.
UA27224C2 (uk) Арилалкіламіни, спосіб їх одержання та фармацевтична композиція
ATE181829T1 (de) Gaba-erge modulation des augenwachstums
IE810785L (en) Anti-inflammatory ophthalmic composition
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ES8802420A1 (es) Un procedimiento para la preparacion de un derivado de acido 5-imidazolcarboxilico
EP0422068A4 (en) Pharmacological treatment of ocular development
ES2058029A1 (es) Proceso para la produccion de sales del acido clavulanico.
EP0249938A3 (en) Imidazolesulfonamide derivatives,herbicides and a method for inhibiting growth of undesirable plants
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
ES8105969A1 (es) Procedimiento para preparar derivados fluorados de metil-be ta-alanina.
NZ335042A (en) Tranilast (N-(3,4-dimethoxycinnamoyl)anthranilic acid) as a secondary cataract inhibitor
IL126725A0 (en) Compositions comprising a nitrone compound for use in treating ocular inflammation
IL133414A0 (en) Benzo (5, 6) cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
BE899299A (fr) Composition fongicide a base de tris ethyl phosphonate d'aluminium
AU575022B2 (en) Antiviral 5-halovinyl-2'-deoxyuridines
MX9701764A (es) Derivados de imidoacidos.
ES8302634A1 (es) Procedimiento de preparacion de derivados del acido metilen-2-succinamico
ATE158796T1 (de) Pharmazeutisch wirksame enantiomere
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
ES2007598A6 (es) Composicion a base de derivados de fosfonatos amonicos y procedimientopara regular con ella el crecimiento de las plantas.
IE43848L (en) Pharmaceutical compositions
UA19048A (uk) Стимулятор росту рослиh
ES8609351A1 (es) Procedimiento para la preparacion de composiciones farmaceuticas hidrosolubles a base de sales del acido (-) cis-1, 2-epoxi-propilfosfonico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee